Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion

Juan Carlos Mesa Guti&eacute;rrez, Luis Arias Barquet, Josep Maria Caminal Mitjana, Sergi Prades Almolda, N&ugrave;ria Planas Dom&egrave;nech, Octavi Pujol Goita, Marc Rubio Caso, Jorge Arruga GinebredaDepartment of Ophthalmology, Hospital Universitari de Bellvitge, L&amp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Juan Carlos Mesa Guti&eacute;rrez, Luis Arias Barquet, Josep Maria Caminal Mitjana, Sergi Prades Almolda, N&ugrave;ria Planas Dom&egrave;nech, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e4ad3330c3554ab49b25280bd144d86b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e4ad3330c3554ab49b25280bd144d86b
record_format	dspace
spelling	oai:doaj.org-article:e4ad3330c3554ab49b25280bd144d86b2021-12-02T07:37:29ZIntravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion1177-54671177-5483https://doaj.org/article/e4ad3330c3554ab49b25280bd144d86b2008-09-01T00:00:00Zhttp://www.dovepress.com/intravitreal-bevacizumab-avastin-in-the-treatment-of-macular-edema-sec-a2152https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Juan Carlos Mesa Guti&eacute;rrez, Luis Arias Barquet, Josep Maria Caminal Mitjana, Sergi Prades Almolda, N&ugrave;ria Planas Dom&egrave;nech, Octavi Pujol Goita, Marc Rubio Caso, Jorge Arruga GinebredaDepartment of Ophthalmology, Hospital Universitari de Bellvitge, L&rsquo;Hospitalet de Llobregat, Barcelona, SpainObjective: To evaluate efficacy and safety of intravitreal injections of bevacizumab in the treatment of macular edema secondary to retinal vein occlusion (RVO).Methods: Prospective study, noncomparative, interventional case series. Twelve consecutive patients (12 eyes) with macular edema associated with nonischemic retinal vein occlusion were treated with intravitreal bevacizumab (1.25 mg). All subjects underwent standardized ophthalmic evaluation at baseline and at weeks 1, 4, 12, and 24, consisting of visual acuity (VA) measurement using ETDRS charts, and imaging with ocular coherence tomography evaluating changes in foveal thickness (FT) and macular volume (MV).Results: The median age was 66 years (&plusmn; 4.16), and the median duration of symptoms was 4 months (&plusmn; 1.81). There were six cases of inferior branch vein occlusion and six cases of superior branch retinal vein occlusion. Mean VA improved from 1.32 &plusmn; 0.24 (logMAR values) at baseline to 0.8 &plusmn; 0.15 (p = 0.0003) at the 6-month follow-up. The macular edema responded promptly, and a trend to restoration of normal macular anatomy was observed at by the seventh day. Mean FT improved from 615.50 &plusmn; 116.29 microns to 420 &plusmn; 72.53 microns (p = 0.001), and the mean MV improved from 19.81 &plusmn; 2.31mm3 to 9.23 &plusmn; 1.38 (p = 0.0001) at the 6-month follow-up.Keywords: Bevacizumab, retinal vein occlusion, intravitreal injection, vascular endothelial growth factor Juan Carlos Mesa Guti&eacute;rrezLuis Arias BarquetJosep Maria Caminal MitjanaSergi Prades AlmoldaN&ugrave;ria Planas Dom&egrave;nechet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 4, Pp 787-791 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Juan Carlos Mesa Guti&eacute;rrez Luis Arias Barquet Josep Maria Caminal Mitjana Sergi Prades Almolda N&ugrave;ria Planas Dom&egrave;nech et al Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
description	Juan Carlos Mesa Guti&eacute;rrez, Luis Arias Barquet, Josep Maria Caminal Mitjana, Sergi Prades Almolda, N&ugrave;ria Planas Dom&egrave;nech, Octavi Pujol Goita, Marc Rubio Caso, Jorge Arruga GinebredaDepartment of Ophthalmology, Hospital Universitari de Bellvitge, L&rsquo;Hospitalet de Llobregat, Barcelona, SpainObjective: To evaluate efficacy and safety of intravitreal injections of bevacizumab in the treatment of macular edema secondary to retinal vein occlusion (RVO).Methods: Prospective study, noncomparative, interventional case series. Twelve consecutive patients (12 eyes) with macular edema associated with nonischemic retinal vein occlusion were treated with intravitreal bevacizumab (1.25 mg). All subjects underwent standardized ophthalmic evaluation at baseline and at weeks 1, 4, 12, and 24, consisting of visual acuity (VA) measurement using ETDRS charts, and imaging with ocular coherence tomography evaluating changes in foveal thickness (FT) and macular volume (MV).Results: The median age was 66 years (&plusmn; 4.16), and the median duration of symptoms was 4 months (&plusmn; 1.81). There were six cases of inferior branch vein occlusion and six cases of superior branch retinal vein occlusion. Mean VA improved from 1.32 &plusmn; 0.24 (logMAR values) at baseline to 0.8 &plusmn; 0.15 (p = 0.0003) at the 6-month follow-up. The macular edema responded promptly, and a trend to restoration of normal macular anatomy was observed at by the seventh day. Mean FT improved from 615.50 &plusmn; 116.29 microns to 420 &plusmn; 72.53 microns (p = 0.001), and the mean MV improved from 19.81 &plusmn; 2.31mm3 to 9.23 &plusmn; 1.38 (p = 0.0001) at the 6-month follow-up.Keywords: Bevacizumab, retinal vein occlusion, intravitreal injection, vascular endothelial growth factor
format	article
author	Juan Carlos Mesa Guti&eacute;rrez Luis Arias Barquet Josep Maria Caminal Mitjana Sergi Prades Almolda N&ugrave;ria Planas Dom&egrave;nech et al
author_facet	Juan Carlos Mesa Guti&eacute;rrez Luis Arias Barquet Josep Maria Caminal Mitjana Sergi Prades Almolda N&ugrave;ria Planas Dom&egrave;nech et al
author_sort	Juan Carlos Mesa Guti&eacute;rrez
title	Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_short	Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_full	Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_fullStr	Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_full_unstemmed	Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_sort	intravitreal bevacizumab (avastin) in the treatment of macular edema secondary to retinal vein occlusion
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/e4ad3330c3554ab49b25280bd144d86b
work_keys_str_mv	AT juancarlosmesagutiampeacuterrez intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion AT luisariasbarquet intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion AT josepmariacaminalmitjana intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion AT sergipradesalmolda intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion AT nampugraveriaplanasdomampegravenech intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion AT etal intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion
_version_	1718399311825338368

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion

Ejemplares similares